a 2024

Two years' experience with the Czech population pilot programme for lung cancer early detection

HEJDUK, Karel; Martina KOZIAR-VASAKOVA; Ivana CIERNA-PETEROVA; Hynek MIRKA; Bohumil SEIFERT et. al.

Základní údaje

Originální název

Two years' experience with the Czech population pilot programme for lung cancer early detection

Autoři

HEJDUK, Karel; Martina KOZIAR-VASAKOVA; Ivana CIERNA-PETEROVA; Hynek MIRKA; Bohumil SEIFERT; Jana SKRICKOVA; Vladimir KOBLIZEK; Alena MENSIKOV; Marcela KOUDELKOVA; Renata CHLOUPKOVA; Ondrej NGO; Nikola STOURAC a Ondrej MAJEK

Vydání

ERS Congress 2024 7.-11.9.2024 Vienna, 2024

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30230 Other clinical medicine subjects

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 21.000

Kód RIV

RIV/00216224:14110/24:00138351

Organizační jednotka

Lékařská fakulta

ISSN

UT WoS

001361501200090

Klíčová slova česky

lung cancer; low-dose CT; LDCT; clinical trial

Klíčová slova anglicky

lung cancer; low-dose CT; LDCT; clinical trial

Štítky

Příznaky

Mezinárodní význam
Změněno: 4. 4. 2025 13:59, Bc. Hana Vladíková, BBA

Anotace

V originále

The Czech population pilot programme for lung cancer early detection was initiated in 2022. Target population comprises men and women aged 55–74 years with smoking history (at least 20 pack-years), former of current smokers. The estimated number of persons meeting the criteria is 250,000 to 500,000. GPs offer the programme and refer participants to a pneumologist, individuals can also contact their pneumologist directly. Pneumologists perform complex pulmonary examinations, refer patients for low-dose CT (LDCT) and navigate them in the healthcare system. LDCT is provided only at radiological departments certified by the Ministry of Health. The programme uses LDCT, initially repeated after one year, then after 2 years. The results of two years of project implementation show that over 20,000 people underwent initial risk assessment (77 % by GPs, 13 % by pneumologist), 10,000 people underwent lung examinations, and first LDCT was performed in 6,500 people. On the basis of the first LDCT examination (or the repeated LDCT examination after an indeterminate result), the majority of patients (89%) were negative. Almost 8% of subjects had an indeterminate result and almost 4% of subjects were positive; those patients were referred to specialized pneumo-onco-surgical centres. The Czech programme has been successfully initiated and is now undergoing continuous monitoring. Estimated process characteristics are in line with expectations from clinical trials.

Návaznosti

90249, velká výzkumná infrastruktura
Název: CZECRIN IV